Myriad Genetics (NASDAQ:MYGN) Issues FY23 Earnings Guidance

Myriad Genetics (NASDAQ:MYGN – Get Free Report) updated its FY23 earnings guidance on Monday. The company provided EPS guidance of ($0.33)-($0.28) for the period, compared to the consensus EPS estimate of ($0.32). The company issued revenue guidance of $747-$753 million, compared to the consensus revenue estimate of $739.22 million. Myriad Genetics Stock Down 4.0 % […]

Related Keywords

United States ,Montreal ,Quebec ,Canada ,American ,Richard Bryan Riggsbee ,Genetics Inc ,Goldman Sachs Group ,Securities Exchange Commission ,Us Bancorp ,Jpmorgan Chase Co ,Metlife Investment Management ,American Century Companies Inc ,Genetics Company Profile ,Myriad Genetics ,Get Free Report ,Genetics Stock Down ,Bryan Riggsbee ,Exchange Commission ,Century Companies ,Montreal Can ,Life Investment Management ,Myrisk Hereditary Cancer Test ,Germline Companion Diagnostic Test ,Companion Diagnostic Test ,Myriad Genetics Daily ,Nasdaq Mygn ,Mygn ,Medical ,62855j10 ,Guidance ,Earnings ,Preannouncement ,